1800 Williams St., Suite 200 • Denver, CO 80218
Phone 303-388-4876 • Fax 303-336-2193 • Toll Free 1-800-891-7622

URL http://www.rockymountainbmt.com/news/Single-dose-pegfilgrastim-induces-stem-cell-mobilization-in-malignant-lymphoma-or-multiple-myeloma-4909.html

Single-dose pegfilgrastim induces stem cell mobilization in malignant lymphoma or multiple myeloma

10-09-2006

Single-dose pegfilgrastim after chemotherapy induces stem cell mobilization in malignant lymphoma or multiple myeloma patients.

According to a recently published study from Germany, "A single injection of pegfilgrastim has been shown to be equivalent to daily filgrastim in enhancing neutrophil recovery after chemotherapy, whereas the experiences with pegfilgrastim in mobilization of peripheral blood progenitor cells (PBPCs) are limited.

"Forty unselected patients with lymphoma or multiple myeloma were treated with different chemotherapy regimens followed by 6 mg of pegfilgrastim for mobilization of autologous PBPCs. Patients with an inadequate mobilization (blood CD34+ cells {{<=}}10/mcL after nadir) were given additional daily doses of 10 mcg per kg unconjugated filgrastim."

"A median blood CD34+ peak concentration of 81 per mcL (range, 10-565/mcL) was found in 30 patients, who had only received pegfilgrastim, compared to 13 per mcL (median, range 4-71/mcL; p<0.001) in 10 poor mobilizing patients with additional filgrastim.

"The median yield of CD34+ cells was 9.8x106 per kg (range, 1.5-88.1) after pegfilgrastim only versus 2.5x106 (range, 1.7-7.0) in poor mobilizers. Patients who needed additional cytokine administration were those with a more extensive previous antineoplastic treatment and mobilizing regimens containing PBPC toxic agents," said researchers.

"The results confirm the efficacy and feasibility of PBPC mobilization with chemotherapy and single-dose pegfilgrastim in patients with lymphoproliferative malignancies," F. Kroschinsky and colleagues at University Hospital Dresden reported.

"In less heavily pretreated patients," concluded the authors, "6 mg of pegfilgrastim after chemotherapy induced an adequate mobilization, whereas dose and schedule in patients after numerous cytotoxic regimens need further investigation."

Kroschinsky and colleagues published their study in Transfusion (Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion, 2006;46(8):1417-1423).

For more information, contact F. Kroschinsky, TU Dresden, University of Klinikum, Medical Klin & Poliklin 1, Fetscherstr 74, D-01307 Dresden, Germany.

Publisher contact information for the journal Transfusion is: Blackwell Publishing, 9600 Garsington Rd., Oxford OX4 2DQ, Oxon, England.

Keywords: Dresden, Germany, Filgrastim, Multiple Myeloma, Stem Cell Mobilization, Malignant Lymphoma, Chemotherapy.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.